医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Oxea Announces Price Increase for Carboxylic Acids

2013年01月05日 AM12:25
このエントリーをはてなブックマークに追加


 

DALLAS

Oxea will increase list and off-list prices on the product below effective January 15, 2013, or as contracts allow.

Product   North America   Asia, Middle East
    USD/lb USD/mt
2-Ethylhexanoic acid 0,03 100

Oxea is a global manufacturer of oxo intermediates and oxo derivatives, such as alcohols, polyols, carboxylic acids, specialty esters, and amines. These products are used for the production of high-quality coatings, lubricants, cosmetics and pharmaceutical products, flavorings and fragrances, printing inks and plastics. In 2011, Oxea generated revenue of about EUR 1.5 billion with its 1,365 employees in Europe, the Americas and Asia.

For more information, visit www.oxea-chemicals.com.

CONTACT

Commercial contact:
OXEA Corporation, 1505 West LBJ Freeway,
Dallas, TX, 75234, USA
Cristóbal Ascencio, Vice President
Oxo-Derivatives
Phone +1 972-481-2700, fax +1 972-481-6023
info@oxea-chemicals.com,
www.oxea-chemicals.com
or
Press
contact:

OXEA GmbH, Otto-Roelen-Strasse 3, D-46147 Oberhausen
Birgit
Reichel, phone +49 (0) 208-693-3112, fax +49 (0) 208-693-3101
birgit.reichel@oxea-chemicals.com,
www.oxea-chemicals.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates